Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


Articles published in J Med Virol

Retrieve available abstracts of 300 articles:
HTML format



Single Articles


    April 2021
  1. BULFONI M, Pravisani R, Dalla E, Cesselli D, et al
    miRNA expression profiles in liver grafts of HCV and HIV/HCV infected recipients, six months after liver transplantation.
    J Med Virol. 2021 Apr 5. doi: 10.1002/jmv.26999.
    PubMed     Abstract available


    March 2021
  2. ELHENCE A, Singh A, Anand A, Kumar R, et al
    Real-World Re-Treatment Outcomes of Direct-Acting Antiviral Therapy Failure in Patients with Chronic Hepatitis C.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26971.
    PubMed     Abstract available


  3. BEN DHIFALLAH I, Ayouni K, Jmel H, Kammoun W, et al
    Strong association of functional polymorphism in IL-12B with susceptibility to Chronic Hepatitis B in Tunisia.
    J Med Virol. 2021 Mar 19. doi: 10.1002/jmv.26946.
    PubMed     Abstract available


  4. FEDORCHENKO SV, Martynovych T, Klimenko Z, Solianyk I, et al
    Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin in patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous with first- and second-generation NS5A inhibitors.
    J Med Virol. 2021 Mar 11. doi: 10.1002/jmv.26935.
    PubMed     Abstract available


  5. HU Q, Wang Q, Zhang Y, Tao S, et al
    Baseline serum exosome-derived miRNAs predict HBeAg seroconversion in chronic hepatitis B patients treated with peginterferon.
    J Med Virol. 2021 Mar 5. doi: 10.1002/jmv.26916.
    PubMed     Abstract available


    December 2020
  6. MIRANDA NTGP, de Souza RL, Monteiro JC, Costa IB, et al
    Seroprevalence of HBV and HCV in female sex workers from four cities in the state of Para, northern Brazil.
    J Med Virol. 2020 Dec 25. doi: 10.1002/jmv.26759.
    PubMed     Abstract available


  7. BAKI AA, Haque W, Giti S, Khan AA, et al
    Hepatitis E virus genotype 1f outbreak in Bangladesh, 2018.
    J Med Virol. 2020 Dec 17. doi: 10.1002/jmv.26739.
    PubMed     Abstract available


  8. SARKAR S, Khanna P, Singh AK
    Impact of COVID-19 in patients with concurrent co-infections: a systematic review and meta-analyses.
    J Med Virol. 2020 Dec 17. doi: 10.1002/jmv.26740.
    PubMed     Abstract available


    November 2020
  9. ALVARADO-ESQUIVEL C, Gutierrez-Martinez VD, Ramirez-Valles EG, Sifuentes-Alvarez A, et al
    Hepatitis E Virus infection and waste pickers: a case-control seroprevalence study.
    J Med Virol. 2020 Nov 24. doi: 10.1002/jmv.26688.
    PubMed     Abstract available


  10. CHUA JV, Ntem-Mensah A, Abutaleb A, Husson J, et al
    Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: an open-label study.
    J Med Virol. 2020 Nov 5. doi: 10.1002/jmv.26652.
    PubMed     Abstract available


    October 2020
  11. GONG S, Hao X, Bi Y, Yang C, et al
    Hepatitis E viral infection regulates estrogen signaling pathways: inhibition of the cAMPK-PKA -CREB and PI3K-AKT-mTOR signaling pathways.
    J Med Virol. 2020 Oct 31. doi: 10.1002/jmv.26641.
    PubMed     Abstract available


  12. SINGH AK, Rooge SB, Varshney A, Vasudevan M, et al
    Identification of miRNAs associated with dendritic cell dysfunction during Acute and Chronic Hepatitis B virus infection.
    J Med Virol. 2020 Oct 27. doi: 10.1002/jmv.26629.
    PubMed     Abstract available


    September 2020
  13. AYOUNI K, Kharroubi G, Mallekh R, Hammami W, et al
    Seroprevalence of hepatitis A virus infection in Central-West of Tunisia.
    J Med Virol. 2020 Sep 28. doi: 10.1002/jmv.26563.
    PubMed     Abstract available


  14. BARUAH V, Tiwari D, Hazam RK, Bose M, et al
    Prognostic, clinical and therapeutic importance of RANTES-CCR5 axis in hepatitis A infection: A multi-approach study.
    J Med Virol. 2020 Sep 25. doi: 10.1002/jmv.26557.
    PubMed     Abstract available


  15. WANG ML, Liao J, Ye F, Tao YC, et al
    Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients.
    J Med Virol. 2020 Sep 19. doi: 10.1002/jmv.26529.
    PubMed     Abstract available


  16. TAMORI A, Kimura K, Kioka K, Enomoto H, et al
    Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation.
    J Med Virol. 2020 Sep 17. doi: 10.1002/jmv.26526.
    PubMed     Abstract available


  17. HIGUCHI M, Tamaki N, Kurosaki M, Inada K, et al
    Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic Hepatitis C.
    J Med Virol. 2020 Sep 5. doi: 10.1002/jmv.26490.
    PubMed     Abstract available


    August 2020
  18. WOLF JM, Pereira VRZB, Simon D, Lunge VR, et al
    Evolutionary History of Hepatitis B Virus Genotype H.
    J Med Virol. 2020 Aug 27. doi: 10.1002/jmv.26463.
    PubMed     Abstract available


  19. KUMAR R, Chan KP, Ekstrom VSM, Wong JCC, et al
    Hepatitis C Virus antigen detection is an appropriate test for screening and early diagnosis of hepatitis C virus infection in at-risk populations and immunocompromised hosts.
    J Med Virol. 2020 Aug 14. doi: 10.1002/jmv.26433.
    PubMed     Abstract available


  20. REN F, Li W, Zhao S, Wang L, et al
    A3G-induced mutations show low prevalence and exhibit plus strand regional distribution in hepatitis B virus DNA from patients with non-hepatocellular carcinoma (HCC) and HCC.
    J Med Virol. 2020 Aug 11. doi: 10.1002/jmv.26418.
    PubMed     Abstract available


  21. AUZIN AM, Slavenburg S, Peters C, Boland G, et al
    Rapid, random-access, quantification of hepatitis B virus using the Cepheid Xpert(R) HBV Viral Load assay.
    J Med Virol. 2020 Aug 6. doi: 10.1002/jmv.26392.
    PubMed     Abstract available


  22. RIDRUEJO E, Pinero F, Mendizabal M, Cheinquer H, et al
    Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.
    J Med Virol. 2020 Aug 4. doi: 10.1002/jmv.26383.
    PubMed     Abstract available


  23. UCHIDA Y, Nakao M, Tsuji S, Uemura H, et al
    Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    J Med Virol. 2020;92:1370.
    PubMed    


    July 2020
  24. TRIPATHY AS, Sharma M, Thorat NC, Jadhav S, et al
    An outbreak of hepatitis E in Yavatmal, India, 2019.
    J Med Virol. 2020 Jul 31. doi: 10.1002/jmv.26377.
    PubMed     Abstract available


  25. PATACCINI G, Andrea Berini C, Rene Pedrozo W, Marcela Biglione M, et al
    First molecular epidemiological study of hepatitis B and D in individuals infected with human T- lymphotropic virus 1/2 from Argentina.
    J Med Virol. 2020 Jul 29. doi: 10.1002/jmv.26366.
    PubMed     Abstract available


  26. FAROOQ M, Rauf M, Tahir F, Manzoor S, et al
    "A comparative analysis of interferons and direct-acting antivirals on the expression of genes involved in hepatitis C pathogenesis".
    J Med Virol. 2020 Jul 24. doi: 10.1002/jmv.26351.
    PubMed     Abstract available


  27. RAMASWAMY M, Bruden D, Nolen LD, Mosites E, et al
    Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska.
    J Med Virol. 2020 Jul 22. doi: 10.1002/jmv.26327.
    PubMed     Abstract available


  28. LI MH, Chen QQ, Zhang L, Lu HH, et al
    Association of cytokines with hepatitis B virus and its antigen.
    J Med Virol. 2020 Jul 14. doi: 10.1002/jmv.26301.
    PubMed     Abstract available


  29. AL-SAFFAR OB, Ad'hiah AH
    Genetic variants in IL4RA, IL6, and IL12B genes and susceptibility to hepatitis B and C virus infections among Iraqi patients.
    J Med Virol. 2020 Jul 11. doi: 10.1002/jmv.26297.
    PubMed     Abstract available


  30. MODIYINJI AF, Rivero-Juarez A, Lopez-Lopez P, Atsama MA, et al
    First molecular characterization of the hepatitis E virus in humans in Cameroon: Confirmation of the HEV outbreak in Touboro, North-Cameroon.
    J Med Virol. 2020 Jul 8. doi: 10.1002/jmv.26277.
    PubMed     Abstract available


  31. MARTINEZ ALFREDO P, Pereson Matias J, Perez Paula S, Ines BM, et al
    Prevalence of Hepatitis E virus in children from Northeast of Argentina.
    J Med Virol. 2020 Jul 8. doi: 10.1002/jmv.26274.
    PubMed     Abstract available


  32. SATO N, Watanabe S, Miura K, Morimoto N, et al
    Clinical and virologic features of hepatitis E virus infection at a university hospital in Japan between 2000 and 2019.
    J Med Virol. 2020 Jul 1. doi: 10.1002/jmv.26248.
    PubMed     Abstract available


    June 2020
  33. DEBES JD, Groothuismink ZMA, de Man RA, Boonstra A, et al
    Association Between a Progesterone Receptor Mutation and Hepatitis E Sero-Positivity in Liver Transplant Recipients.
    J Med Virol. 2020 Jun 30. doi: 10.1002/jmv.26236.
    PubMed     Abstract available


  34. BANGUESES F, Abin-Carriquiry JA, Cancela F, Curbelo J, et al
    Serological and molecular prevalence of Hepatitis E Virus (HEV) among blood donors from Uruguay.
    J Med Virol. 2020 Jun 27. doi: 10.1002/jmv.26231.
    PubMed     Abstract available


  35. TIAN D, Yugo DM, Kenney SP, Lynn Heffron C, et al
    Dissecting the potential role of hepatitis E virus ORF1 non-structural gene in cross-species infection by using intergenotypic chimeric viruses.
    J Med Virol. 2020 Jun 26. doi: 10.1002/jmv.26226.
    PubMed     Abstract available


  36. KO K, Nagashima S, Yamamoto C, Takahashi K, et al
    18 Years Follow-up Cohort Study on Hepatitis B and C Virus Infections Related Long Term Prognosis among Hemodialysis Patients in Hiroshima.
    J Med Virol. 2020 Jun 24. doi: 10.1002/jmv.26215.
    PubMed     Abstract available


  37. HAN W, Li J, Zhou H, Qian J, et al
    Identification of the association of CD28(+) CD244(+) Tc17/IFN-gamma cells with chronic hepatitis C virus infection.
    J Med Virol. 2020 Jun 22. doi: 10.1002/jmv.26205.
    PubMed     Abstract available


  38. ABO EL-KHAIR SM, El-Alfy HA, Elsamanoudy AZ, Elhammady D, et al
    Development of a novel glycated protein-based fibrosis prediction score for determination of significant liver fibrosis in HCV-infected patients, a preliminary study.
    J Med Virol. 2020 Jun 19. doi: 10.1002/jmv.26204.
    PubMed     Abstract available


  39. LI Y, Li C, Wang J, Zhu C, et al
    A case series of COVID-19 patients with chronic hepatitis B virus infection.
    J Med Virol. 2020 Jun 19. doi: 10.1002/jmv.26201.
    PubMed     Abstract available


  40. XIAO L, Wu X, Zhang F, Wang J, et al
    Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1 b hepatitis C infection.
    J Med Virol. 2020 Jun 11. doi: 10.1002/jmv.26161.
    PubMed     Abstract available


  41. SEBASTIAO CS, Neto Z, Jandondo D, Mirandela M, et al
    HIV, hepatitis B virus, hepatitis C virus, and syphilis among pregnant women attending antenatal care in Luanda, Angola: seroprevalence and risk factors.
    J Med Virol. 2020 Jun 9. doi: 10.1002/jmv.26148.
    PubMed     Abstract available


    May 2020
  42. MOHAMADI M, Azarbayjani K, Mozhgani SH, Bamdad T, et al
    Hepatitis C virus alternative reading frame protein (ARFP): production, features and pathogenesis.
    J Med Virol. 2020 May 29. doi: 10.1002/jmv.26091.
    PubMed     Abstract available


  43. LIU Y, Zhao ZH, Lv XQ, Tang YW, et al
    Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models.
    J Med Virol. 2020 May 19. doi: 10.1002/jmv.26025.
    PubMed     Abstract available


  44. WAHID B, Shami K, Joiya SA, Ozuyar SEG, et al
    Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin).
    J Med Virol. 2020 May 17. doi: 10.1002/jmv.25931.
    PubMed     Abstract available


  45. ODJIDJA EN, Longo VL, Rizzatti G, Bandoh S, et al
    Coronavirus Disease 2019 and Viral Hepatitis coinfection: Provide guidelines for integrated screening and treatment.
    J Med Virol. 2020 May 15. doi: 10.1002/jmv.26021.
    PubMed     Abstract available


  46. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection.
    J Med Virol. 2020 May 6. doi: 10.1002/jmv.25984.
    PubMed     Abstract available


  47. AMSTUTZ A, Nsakala BL, Cheleboi M, Lejone TI, et al
    Low rates of active hepatitis B and C infections among adults and children living with HIV and taking antiretroviral therapy: a multicenter screening study in Lesotho.
    J Med Virol. 2020 May 5. doi: 10.1002/jmv.25970.
    PubMed     Abstract available


    April 2020
  48. KOC OM, Robaeys G, Topal H, Bielen R, et al
    Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: a long-term observational cohort study.
    J Med Virol. 2020 Apr 28. doi: 10.1002/jmv.25950.
    PubMed     Abstract available


  49. JAMIL Z, Waheed Y, Ahsan O, Najmi MH, et al
    Familial Clustering of Hepatitis C Virus in Pakistani Population.
    J Med Virol. 2020 Apr 22. doi: 10.1002/jmv.25926.
    PubMed     Abstract available


  50. KODANI M, Poe A, Drobeniuc J, Hayden T, et al
    Determination of potential biotin interference on accuracy of results of serologic assays for various viral hepatitis markers.
    J Med Virol. 2020 Apr 14. doi: 10.1002/jmv.25880.
    PubMed     Abstract available


  51. AVELLON A, Ala A, Diaz A, Domingo D, et al
    Clinical Performance of Determine(TM) HBsAg 2 rapid test for hepatitis B detection.
    J Med Virol. 2020 Apr 9. doi: 10.1002/jmv.25862.
    PubMed     Abstract available


    March 2020
  52. JAMSHIDI S, Bokharaei-Salim F, Esghaei M, Bastani MN, et al
    Occult HCV and Occult HBV Co-infection in Iranian Human Immunodeficiency Virus-Infected Individuals.
    J Med Virol. 2020 Mar 31. doi: 10.1002/jmv.25808.
    PubMed     Abstract available


  53. BAI X, Ma X, Li M, Li X, et al
    Field applicable detection of hepatitis B virus using internal controlled duplex recombinase-aided amplification assay and lateral flow dipstick assay.
    J Med Virol. 2020 Mar 19. doi: 10.1002/jmv.25778.
    PubMed     Abstract available


  54. MARGUSINO-FRAMINAN L, Perez EB, Cid-Silva P, Rodriguez-Sotelo A, et al
    Effectiveness and Safety of Direct-Acting Antivirals in Hepatitis C Infected Patients with Mental Disorders: Results in Real Clinical Practice.
    J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25772.
    PubMed     Abstract available


  55. WANG X, Pan Y, Chen J, Luo J, et al
    The excretion rate and stability of HAAg in human fecal samples after live attenuated hepatitis A vaccination.
    J Med Virol. 2020 Mar 5. doi: 10.1002/jmv.25747.
    PubMed     Abstract available


  56. MUSHTAQ S, Mansoor A, Umar M, Khan A, et al
    Direct-acting antiviral agents in the treatment of chronic Hepatitis C - Real-life experience from clinical practices in Pakistan.
    J Med Virol. 2020 Mar 4. doi: 10.1002/jmv.25745.
    PubMed     Abstract available


  57. MEI X, Dai F, Zou J, Zhang H, et al
    Quasispecies dynamics of a hepatitis E virus 4 from the feces and liver biopsy of an acute hepatitis E patient during virus clearance.
    J Med Virol. 2020 Mar 4. doi: 10.1002/jmv.25746.
    PubMed     Abstract available


    February 2020
  58. RAHEEL M, Choga WT, Blackard JT
    The distribution of hepatitis B virus surface antigen polymorphisms at positions associated with vaccine escape.
    J Med Virol. 2020 Feb 27. doi: 10.1002/jmv.25730.
    PubMed     Abstract available


  59. LIU L, Zhu J, Yang J, Li X, et al
    GP73 Facilitates Hepatitis B Virus Replication by Repressing the NF-kappaB Signaling Pathway.
    J Med Virol. 2020 Feb 20. doi: 10.1002/jmv.25718.
    PubMed     Abstract available


  60. LU C, Feng Y, Sun X, Li N, et al
    Tree Shrew Bone Marrow-Derived Mesenchymal Stem Cells Express CD81, OCLN, and miR-122, Facilitating the Entire Hepatitis C Virus Life Cycle.
    J Med Virol. 2020 Feb 13. doi: 10.1002/jmv.25710.
    PubMed     Abstract available


  61. BURA M, Lagiedo-Zelazowska M, Michalak M, Mozer-Lisewska I, et al
    Exposure to hepatitis E virus (HEV) in hemodialysis patients from west-central Poland.
    J Med Virol. 2020 Feb 4. doi: 10.1002/jmv.25696.
    PubMed     Abstract available


  62. DE OLIVEIRA TM, Vieira NSG, Sepp TDS, Souto FJD, et al
    Recent Trends in Hepatitis a Incidence in Brazil.
    J Med Virol. 2020 Feb 3. doi: 10.1002/jmv.25694.
    PubMed     Abstract available


    January 2020
  63. TAMAKI N, Kurosaki M, Nakanishi H, Itakura J, et al
    Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B.
    J Med Virol. 2020 Jan 29. doi: 10.1002/jmv.25692.
    PubMed     Abstract available


  64. YANG J, Xiong Y, Zhou L, Huang Y, et al
    Soluble E-cadherin is associated with oxidative stress in patients with chronic HBV infection.
    J Med Virol. 2020;92:34-44.
    PubMed     Abstract available


    December 2019
  65. FUCHS M, Monto A, Brau N, Charafeddine M, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for Chronic HCV Infection in US Veterans with Psychiatric Disorders.
    J Med Virol. 2019 Dec 12. doi: 10.1002/jmv.25655.
    PubMed     Abstract available


  66. KIM M, Kyung Lee Y, Park B, Jun Oh D, et al
    Hepatitis virus B and C infections are associated with an increased risk of non-Hodgkin lymphoma: A nested case-control study using a national sample cohort.
    J Med Virol. 2019 Dec 11. doi: 10.1002/jmv.25653.
    PubMed     Abstract available


    November 2019
  67. UCHIDA Y, Nakao M, Tsuji S, Uemura H, et al
    Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    J Med Virol. 2019 Nov 28. doi: 10.1002/jmv.25644.
    PubMed     Abstract available


  68. OMRAN NM, El-Sherbini SM, Hegazy O, Elshaarawy AA, et al
    Crosstalk between miR-215 and Epithelial-Mesenchymal Transition (EMT) specific markers (E- and N-cadherin) in different stages of chronic HCV Infection.
    J Med Virol. 2019 Nov 26. doi: 10.1002/jmv.25637.
    PubMed     Abstract available


  69. JIANG Q, Mao R, Wu J, Chang L, et al
    Platelet Activation During Chronic Hepatitis B Infection Exacerbates Liver Inflammation and Promotes Fibrosis.
    J Med Virol. 2019 Nov 26. doi: 10.1002/jmv.25641.
    PubMed     Abstract available


  70. DEL-RIOS NHA, de Araujo LA, Martins RMB, Guimaraes RA, et al
    Molecular and Epidemiological Aspects of Hepatitis C Virus Infection Among Crack Cocaine Users.
    J Med Virol. 2019 Nov 20. doi: 10.1002/jmv.25632.
    PubMed     Abstract available


  71. RODRIGUEZ-TAJES S, Perpinan E, Leonel T, Lens S, et al
    Low seroprevalence and zero incidence rate of hepatitis E in men who have sex with men during a hepatitis A outbreak.
    J Med Virol. 2019 Nov 19. doi: 10.1002/jmv.25630.
    PubMed     Abstract available


  72. LI N, Fan X, Wang X, Zhang X, et al
    Genetic association of polymorphisms at intergenic region between PRDM1 and ATG5 with hepatitis B virus infection in Han Chinese patients.
    J Med Virol. 2019 Nov 15. doi: 10.1002/jmv.25629.
    PubMed     Abstract available


  73. SHEN S, Lai-Hung Wong G, Kuang Z, van Campenhout MJH, et al
    Development and validation of a model for hepatitis B e Antigen seroconversion in entecavir-treated chronic hepatitis B patients.
    J Med Virol. 2019 Nov 14. doi: 10.1002/jmv.25628.
    PubMed     Abstract available


  74. HUANG J, Jing M, Wang C, Wang M, et al
    The impact of hepatitis B virus infection status on the prevalence of non-alcoholic fatty liver disease: A population-based study.
    J Med Virol. 2019 Nov 6. doi: 10.1002/jmv.25621.
    PubMed     Abstract available


    October 2019
  75. GRABARCZYK P, Kubicka-Russel D, Kopacz A, Liszewski G, et al
    Seronegative hepatitis C virus (HCV) infection in Polish blood donors - virological characteristics of index donations and follow-up observations.
    J Med Virol. 2019 Oct 31. doi: 10.1002/jmv.25617.
    PubMed     Abstract available


  76. MAHMUD S, Chemaitelly HS, Kouyoumjian SP, Kanaani ZA, et al
    Key associations for hepatitis C virus genotypes in the Middle East and North Africa.
    J Med Virol. 2019 Oct 30. doi: 10.1002/jmv.25614.
    PubMed     Abstract available


  77. GU Y, Chen L, Lian Y, Gu L, et al
    Serum HBV Pregenomic RNA Is Correlated with Th1/Th2 Immunity in Treatment-Naive Chronic Hepatitis B Patients.
    J Med Virol. 2019 Oct 23. doi: 10.1002/jmv.25612.
    PubMed     Abstract available


  78. KOC OM, Menart C, Theodore J, Kremer C, et al
    Ethnicity and response to primary three-dose hepatitis B vaccination in employees in the Netherlands, 1983 through 2017.
    J Med Virol. 2019 Oct 17. doi: 10.1002/jmv.25610.
    PubMed     Abstract available


  79. WANG YH, Liao J, Zhang DM, Wu DB, et al
    Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
    J Med Virol. 2019 Oct 14. doi: 10.1002/jmv.25608.
    PubMed     Abstract available


  80. TSAI TC, Deng ST, Hsu CW
    The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.
    J Med Virol. 2019 Oct 10. doi: 10.1002/jmv.25605.
    PubMed     Abstract available


  81. SAITO Y, Imamura M, Uchida T, Osawa M, et al
    Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    J Med Virol. 2019 Oct 4. doi: 10.1002/jmv.25602.
    PubMed     Abstract available


  82. SAMPEDRO A, Casanovas I, Ceballos J, Rodriguez-Granger J, et al
    Comparative evaluation of two immunoassays for serological diagnosis of hepatitis E.
    J Med Virol. 2019 Oct 3. doi: 10.1002/jmv.25601.
    PubMed     Abstract available


    September 2019
  83. ZHENG B, Zhang J, Zheng T, Wang H, et al
    ATP1B3 Cooperates with BST-2 to Promote Hepatitis B Virus Restriction.
    J Med Virol. 2019 Sep 26. doi: 10.1002/jmv.25599.
    PubMed     Abstract available


  84. ABE H, Ushijima Y, Bikangui R, Loembe MM, et al
    Ongoing evolution of hepatitis B virus during viremia in febrile patients in Central Africa.
    J Med Virol. 2019 Sep 20. doi: 10.1002/jmv.25598.
    PubMed     Abstract available


  85. BIN WAHID S, Ain QU, Quraishi A, Wahid B, et al
    Clinical correlation of liver function tests with suppression of cytokine signaling (SOCS1) gene expression in HCV infected patients: a real-world clinical experience.
    J Med Virol. 2019 Sep 19. doi: 10.1002/jmv.25596.
    PubMed     Abstract available


  86. HAO QQ, Wang QH, Xia W, Qian HZ, et al
    Circulating miRNA Expression Profile and Bioinformatics Analysis in Patients with Occult Hepatitis B Virus Infection.
    J Med Virol. 2019 Sep 12. doi: 10.1002/jmv.25594.
    PubMed     Abstract available


  87. XING M, Feng Y, Yao J, Lv H, et al
    Induction of Peripheral Blood T-follicular Helper Cells Expressing ICOS Correlates with Antibody Response to Hepatitis B Vaccination.
    J Med Virol. 2019 Sep 2. doi: 10.1002/jmv.25585.
    PubMed     Abstract available


    August 2019
  88. CUI H, Jin Y, Chen F, Ni H, et al
    Clinicopathological evidence of Hepatitis B Virus infection in the development of gastric adenocarcinoma.
    J Med Virol. 2019 Aug 31. doi: 10.1002/jmv.25584.
    PubMed     Abstract available


  89. LEE KC, Lin CL, Hsu CW, Chang ML, et al
    Decreasing seroprevalence of anti-hepatitis D virus antibodies in the antiviral era with inverse association with hepatitis B virus DNA, Taiwan, 2006 - 2019.
    J Med Virol. 2019 Aug 30. doi: 10.1002/jmv.25582.
    PubMed     Abstract available


  90. JANG ES, Kim KA, Kim YS, Kim IH, et al
    Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: an emphasis on the pretreatment NS5A resistance-associated substitution test.
    J Med Virol. 2019 Aug 26. doi: 10.1002/jmv.25575.
    PubMed     Abstract available


  91. XU J, Tao LL, Ma LX
    Efficacy and safety of telbivudine to prevent mother-to-child transmission of hepatitis B virus in middle and late stage pregnancy with high viral loads.
    J Med Virol. 2019 Aug 9. doi: 10.1002/jmv.25566.
    PubMed     Abstract available


  92. GHAZY AA, Osman EM, Rashwan EA, Gaballah AH, et al
    Relation between micro RNA-21, Transforming Growth Factor Beta and response to treatment among Chronic Hepatitis C Patients.
    J Med Virol. 2019 Aug 1. doi: 10.1002/jmv.25559.
    PubMed     Abstract available


    July 2019
  93. WAHID B
    Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patient previously treated for Tuberculosis.
    J Med Virol. 2019 Jul 26. doi: 10.1002/jmv.25557.
    PubMed     Abstract available


  94. LEI Y, Shao J, Zhao F, Li Y, et al
    Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot-and-mouth disease virus as a bivalent vaccine candidate.
    J Med Virol. 2019 Jul 26. doi: 10.1002/jmv.25554.
    PubMed     Abstract available


  95. MACKEN L, Gelson W, Priest M, Abouda G, et al
    Efficacy of direct acting antivirals: UK real world data from a well characterised predominantly cirrhotic HCV cohort.
    J Med Virol. 2019 Jul 22. doi: 10.1002/jmv.25552.
    PubMed     Abstract available


  96. ROGERS E, Todd M, Pierson FW, Kenney SP, et al
    CD8(+) lymphocytes but not B lymphocytes are required for protection against chronic hepatitis E virus infection in chickens.
    J Med Virol. 2019 Jul 18. doi: 10.1002/jmv.25548.
    PubMed     Abstract available


  97. FENG S, Wang Z, Zhao Y, Ji G, et al
    Long non-coding RNA GAS5 does not regulate HBV replication.
    J Med Virol. 2019 Jul 13. doi: 10.1002/jmv.25547.
    PubMed     Abstract available


  98. MODIYINJI AF, Atsama MA, Monamele CG, Nola M, et al
    Seroprevalence of Hepatitis E virus antibodies in different human populations of Cameroon.
    J Med Virol. 2019 Jul 12. doi: 10.1002/jmv.25545.
    PubMed     Abstract available


  99. IMAI S, Yamana H, Inoue N, Akazawa M, et al
    Validity of administrative database detection of previously-resolved hepatitis B virus in Japan.
    J Med Virol. 2019 Jul 8. doi: 10.1002/jmv.25540.
    PubMed     Abstract available


  100. MARTINEZ AP, Garcia G, Ridruejo E, Culasso AC, et al
    Hepatitis C Virus Genotype 1 Infection: Prevalence of NS5A and NS5B Resistance-Associated Substitutions in Naive Patients from Argentina.
    J Med Virol. 2019 Jul 5. doi: 10.1002/jmv.25536.
    PubMed     Abstract available


    June 2019
  101. TADA T, Toyoda H, Yasuda S, Miyake N, et al
    Natural history of liver-related disease in patients with chronic hepatitis C virus infection: an analysis using a Markov chain model.
    J Med Virol. 2019 Jun 29. doi: 10.1002/jmv.25533.
    PubMed     Abstract available


  102. HUANG J, Xu R, Wang M, Liao Q, et al
    Association of HLA-DQB1*03:01 and DRB1*11:01 with spontaneous clearance of hepatitis C virus in Chinese Li ethnicity, an ethnic group genetically distinct from Chinese Han ethnicity and infected with unique HCV subtype.
    J Med Virol. 2019 Jun 29. doi: 10.1002/jmv.25531.
    PubMed     Abstract available


  103. TONG S, Pan J, Tang J
    Study on the structure optimization and anti-hepatitis B virus activity of novel human La protein inhibitor HBSC11.
    J Med Virol. 2019 Jun 26. doi: 10.1002/jmv.25528.
    PubMed     Abstract available


  104. CHEN Y, Kong Y, Shi L, Zhang X, et al
    Study of the Distribution of Hepatitis B Immunoglobulin in Pregnant Mice Using Small-Animal Imaging Technology.
    J Med Virol. 2019 Jun 17. doi: 10.1002/jmv.25521.
    PubMed     Abstract available


  105. HAGIWARA S, Nishida N, Ida H, Ueshima K, et al
    Switching from Entecavir to Tenofovir alafenamide versus maintaining Entecavir for chronic hepatitis B.
    J Med Virol. 2019 Jun 14. doi: 10.1002/jmv.25515.
    PubMed     Abstract available


  106. MSOMI N, Ndlovu K, Giandhari J, Wilkinson E, et al
    High rate of occult hepatitis B virus infection in haemodialysis units of KwaZulu-Natal, South Africa.
    J Med Virol. 2019 Jun 10. doi: 10.1002/jmv.25510.
    PubMed     Abstract available


  107. MELO DA SILVA E, Kay A, Lobato C, Muwonge R, et al
    Non-F HBV/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon.
    J Med Virol. 2019;91:1081-1086.
    PubMed     Abstract available


  108. KHANIZADEH S, Hasanvand B, Nikoo HR, Anbari K, et al
    Association between miRNA-146a rs2910164 (G/C) polymorphism with the susceptibility to chronic HBV infection and spontaneous viral clearance in an Iranian population.
    J Med Virol. 2019;91:1063-1068.
    PubMed     Abstract available


    May 2019
  109. IFEORAH IM, Faleye TOC, Bakarey AS, Adewumi OM, et al
    Characterization of Hepatitis Delta Virus strains spreading in Abuja, Nigeria.
    J Med Virol. 2019 May 13. doi: 10.1002/jmv.25503.
    PubMed     Abstract available


  110. SLAVOV SN, de Matos Maconetto J, Martinez EZ, Silva-Pinto AC, et al
    PREVALENCE OF HEPATITIS E VIRUS INFECTION IN MULTIPLE TRANSFUSED BRAZILIAN PATIENTS WITH THALASSEMIA AND SICKLE CELL DISEASE.
    J Med Virol. 2019 May 8. doi: 10.1002/jmv.25498.
    PubMed     Abstract available


    April 2019
  111. DING X, Lei Q, Li T, Li L, et al
    Hepatitis B core antigen can regulate NLRP3 inflammasome pathway in HepG2 cells.
    J Med Virol. 2019 Apr 24. doi: 10.1002/jmv.25490.
    PubMed     Abstract available


  112. JACKSON K, Holgate T, Tekoaua R, Nicholson S, et al
    Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing.
    J Med Virol. 2019 Apr 12. doi: 10.1002/jmv.25485.
    PubMed     Abstract available


  113. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    PubMed     Abstract available


  114. ZAYED SA, Zahran NM, Khorshied MM, Abdel-Aziz AO, et al
    Genetic variations in death receptor domain 4 (DR4) gene and the susceptibility to hepatitis C related hepatocellular carcinoma.
    J Med Virol. 2019 Apr 4. doi: 10.1002/jmv.25476.
    PubMed     Abstract available


    March 2019
  115. BARUAH V, Bose S
    Computational identification of Hepatitis-E virus encoded microRNAs and their targets in human.
    J Med Virol. 2019 Mar 28. doi: 10.1002/jmv.25471.
    PubMed     Abstract available


  116. JAVANMARD D, Namaei MH, Farahmand M, Ziaee A, et al
    Molecular and serological characterization of occult hepatitis B virus infection among patients with hemophilia.
    J Med Virol. 2019 Mar 25. doi: 10.1002/jmv.25470.
    PubMed     Abstract available


  117. LIU T, Sun Y, Zhou J, Yang F, et al
    On-treatment changes of serum wisteria floribunda agglutinin-positive mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon alpha add-on therapy.
    J Med Virol. 2019 Mar 24. doi: 10.1002/jmv.25465.
    PubMed     Abstract available


  118. WANG X, Chen Q, Li H, Wang C, et al
    Asymptomatic hepatitis B carriers who were vaccinated at birth.
    J Med Virol. 2019 Mar 18. doi: 10.1002/jmv.25461.
    PubMed     Abstract available


  119. KOC OM, Kremer C, Bielen R, Buscchots D, et al
    Prevalence and risk factors of hepatitis B virus infection in Middle-Limburg Belgium, year 2017: importance of migration.
    J Med Virol. 2019 Mar 14. doi: 10.1002/jmv.25457.
    PubMed     Abstract available


  120. HUANG R, Rao H, Xie Q, Gao Z, et al
    Comparison of Efficacy of Sofosbuvir plus Ribavirin in Chinese Patients with Genotype 3a or 3b HCV Infection.
    J Med Virol. 2019 Mar 12. doi: 10.1002/jmv.25454.
    PubMed     Abstract available


  121. SI J, Li J, Zhang L, Zhang W, et al
    A signal amplification system on a lateral flow immunoassay detecting for hepatitis e antigen in human blood samples.
    J Med Virol. 2019 Mar 9. doi: 10.1002/jmv.25452.
    PubMed     Abstract available


  122. POORDAD F, Bennett M, Sepe TE, Cohen E, et al
    Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with HCV genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
    J Med Virol. 2019 Mar 6. doi: 10.1002/jmv.25448.
    PubMed     Abstract available


    February 2019
  123. HSU CW, Yeh C, Yeh CT
    Maintaining complete virological suppression by reduced doses of nucleos(t)ide analogue in chronic hepatitis B patients.
    J Med Virol. 2019 Feb 28. doi: 10.1002/jmv.25443.
    PubMed     Abstract available


  124. IIDA-UENO A, Enomoto M, Kozuka R, Tamori A, et al
    Switching to tenofovir disoproxil fumarate versus continuing treatment in chronic hepatitis B patients who maintain long-term virological response to entecavir therapy: a randomized trial.
    J Med Virol. 2019 Feb 28. doi: 10.1002/jmv.25442.
    PubMed     Abstract available


  125. BOGLIONE L, Lupia T, Cariti G, Ghisetti V, et al
    Antiviral treatment with PEG-IFN and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: a retrospective analysis.
    J Med Virol. 2019 Feb 22. doi: 10.1002/jmv.25438.
    PubMed     Abstract available


  126. WANG W, Zhao X, Li G, Wang L, et al
    Diagnostic Thresholds and Performance of Non-invasive Fibrosis Scores are Limited by Age in Patients with Chronic Hepatitis B.
    J Med Virol. 2019 Feb 20. doi: 10.1002/jmv.25435.
    PubMed     Abstract available


  127. WEI MT, Le AK, Chang MS, Hsu H, et al
    Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
    J Med Virol. 2019 Feb 18. doi: 10.1002/jmv.25433.
    PubMed     Abstract available


  128. HUANG Y, Wang B, Peng Z, Tang N, et al
    Hepatitis B virus Surface gene mutants in immunoprophylaxis-failed infants from Southern China.
    J Med Virol. 2019 Feb 13. doi: 10.1002/jmv.25430.
    PubMed     Abstract available


  129. BARFI S, Poortahmasebi V, Ofoghi H, Farahmand M, et al
    Measurement of serum hepatitis B surface antibody (HBs-Ab) levels in Iranian autistic children and evaluation of immunological memory after booster dose injection in comparison with controls.
    J Med Virol. 2019 Feb 13. doi: 10.1002/jmv.25429.
    PubMed     Abstract available


  130. HETTA HF, Zahran AM, Mansor SG, Abdel-Malek MO, et al
    Frequency and Implications of Myeloid Derived Suppressor Cells and Lymphocyte Subsets in Egyptian Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma.
    J Med Virol. 2019 Feb 13. doi: 10.1002/jmv.25428.
    PubMed     Abstract available


  131. SONG C, Shan Z, Kang F, Li W, et al
    A 3-year-long investigation of the authenticity of the return results of hepatitis B virus qualitative testing in external quality assessment in East China.
    J Med Virol. 2019 Feb 13. doi: 10.1002/jmv.25431.
    PubMed     Abstract available


  132. GHASEMI A, Zadsar M, Shaiegan M, Samiei S, et al
    Human platelet antigens polymorphisms; Association to the development of liver fibrosis in patients with chronic hepatitis C.
    J Med Virol. 2019 Feb 6. doi: 10.1002/jmv.25423.
    PubMed     Abstract available


  133. LIU C, Wu W, Shang S, Huang E, et al
    Application strategies of serum HBV DNA detection in HBV infection patients: A retrospective study of 5611 specimens.
    J Med Virol. 2019;91:249-257.
    PubMed     Abstract available


    January 2019
  134. KWON JH, Yoo SH, Nam SW, Kim HY, et al
    Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea.
    J Med Virol. 2019 Jan 29. doi: 10.1002/jmv.25412.
    PubMed     Abstract available


  135. KWEON OJ, Lim YK, Kim HR, Kim TH, et al
    Analytical Performance of Newly Developed Rapid Point-of-Care Test for the Simultaneous Detection of Hepatitis A, B, and C Viruses in Serum Samples.
    J Med Virol. 2019 Jan 22. doi: 10.1002/jmv.25405.
    PubMed     Abstract available


  136. JUNIASTUTI, Wahyuddin D, Nihayatussa'adah, Amin M, et al
    ANALYSIS OF GENETIC AND SEROLOGY OF HEPATITIS A VIRUS INFECTION DURING AND AFTER OUTBREAK IN TWO JUNIOR HIGH SCHOOLS IN SURABAYA, INDONESIA.
    J Med Virol. 2019 Jan 19. doi: 10.1002/jmv.25403.
    PubMed     Abstract available


  137. ZHU XB, Zhuo LY, Yue M, Liu M, et al
    Genetic variants in IFIH1 and DDX58 influence HCV clearance in Chinese Han Population.
    J Med Virol. 2019 Jan 11. doi: 10.1002/jmv.25398.
    PubMed     Abstract available


    December 2018
  138. BAVARO DF, Saracino A, Fiordelisi D, Bruno G, et al
    Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV co-infected individuals.
    J Med Virol. 2018 Dec 22. doi: 10.1002/jmv.25385.
    PubMed     Abstract available


  139. TORRES MC, Civetta E, D'amico C, Barbini L, et al
    Hepatitis B virus in Mar del Plata, Argentina: Genomic characterization and evolutionary analysis of subgenotype F1b.
    J Med Virol. 2018 Dec 20. doi: 10.1002/jmv.25383.
    PubMed     Abstract available


  140. YOSRY A, Gamal Eldeen H, Medhat E, Mehrez M, et al
    Ef fi cacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
    J Med Virol. 2018 Dec 14. doi: 10.1002/jmv.25362.
    PubMed     Abstract available


  141. LIU Y, Wang G, Chen Y, Huang R, et al
    HBcAg-induced up-regulated 4-1BB ligand on B cells contributes to B cell hyperactivation during chronic hepatitis B infection.
    J Med Virol. 2018 Dec 14. doi: 10.1002/jmv.25377.
    PubMed     Abstract available


  142. LIAO Y, Gong J, Zhou W, Dong H, et al
    Serum liver fibrosis markers discriminate significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase.
    J Med Virol. 2018 Dec 10. doi: 10.1002/jmv.25364.
    PubMed     Abstract available


  143. BEN S, Yan WJ, Xia W, Juan FJ, et al
    VDR rs7975232/ApaI genetic variation predicts sustained HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with pegylated interferon.
    J Med Virol. 2018 Dec 5. doi: 10.1002/jmv.25373.
    PubMed     Abstract available


  144. SINGH L, Bell TG, Yousif M, Kramvis A, et al
    Response of hepatitis B virus to anti-retroviral treatment containing lamivudine in HBsAg-positive and HBsAg-negative HIV-positive South African adults.
    J Med Virol. 2018 Dec 4. doi: 10.1002/jmv.25375.
    PubMed     Abstract available


  145. COSTA JEF, Morais VMS, Goncales JP, Medeiros AADP, et al
    Occult Hepatitis B Virus Infection in Patients with Leprosy.
    J Med Virol. 2018 Dec 4. doi: 10.1002/jmv.25374.
    PubMed     Abstract available


    November 2018
  146. TRIPATHY AS, Puranik S, Sharma M, Chakraborty S, et al
    Hepatitis E Virus Seroprevalence among Blood Donors in Pune, India.
    J Med Virol. 2018 Nov 29. doi: 10.1002/jmv.25370.
    PubMed     Abstract available


  147. MALAGNINO V, Bottero J, Miailhes P, Lascoux-Combe C, et al
    Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection.
    J Med Virol. 2018 Nov 15. doi: 10.1002/jmv.25360.
    PubMed     Abstract available


  148. KHAN AJ, Saraswat VA, Ranjan P, Parmar D, et al
    Polymorphism in IFNL3/IL28B gene and risk to non-cirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
    J Med Virol. 2018 Nov 15. doi: 10.1002/jmv.25359.
    PubMed     Abstract available


  149. KOC OM, Robaeys G, Yildirim B, Posthouwer D, et al
    The influence of ethnicity on disease outcome in patients with chronic hepatitis B infection.
    J Med Virol. 2018 Nov 1. doi: 10.1002/jmv.25353.
    PubMed     Abstract available


  150. NAGAOKI Y, Imamura M, Nisihda Y, Daijo K, et al
    The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma; comparison with interferon-based therapy.
    J Med Virol. 2018 Nov 1. doi: 10.1002/jmv.25352.
    PubMed     Abstract available


  151. DA COSTA MARQUES BORGES LF, Zalis MG, Santoro-Lopes G, Varella RB, et al
    Hepatitis C virus (HCV) genotypes in hemodialysis patients in Angola.
    J Med Virol. 2018 Nov 1. doi: 10.1002/jmv.25354.
    PubMed     Abstract available


    October 2018
  152. HOLZMAYER V, Hance R, Defechereux P, Grant R, et al
    Identification of Hepatitis B virus genotype I in Thailand.
    J Med Virol. 2018 Oct 23. doi: 10.1002/jmv.25346.
    PubMed     Abstract available


  153. AZARKAR Z, Ziaee M, Ebrahimzadeh A, Sharifzadeh G, et al
    Epidemiology, risk factors and molecular characterization of occult hepatitis B infection among anti-HBc alone subjects.
    J Med Virol. 2018 Oct 21. doi: 10.1002/jmv.25343.
    PubMed     Abstract available


  154. YUGO DM, Cossaboom CM, Heffron CL, Huang YW, et al
    Evidence for an Unknown Agent Antigenically Related to the Hepatitis E Virus in Dairy Cows in the United States.
    J Med Virol. 2018 Oct 14. doi: 10.1002/jmv.25339.
    PubMed     Abstract available


  155. YANG H, Wu J, Yuan Y, Huang W, et al
    Retrospectively Seroprevalence Study on Anti-HEV-IgG antibody in patients with chronic hepatitis or liver cirrhosis in a Chinese teaching hospital.
    J Med Virol. 2018 Oct 11. doi: 10.1002/jmv.25335.
    PubMed     Abstract available


    September 2018
  156. EL HADI H, Benani A, Qmichou Z, Lazar F, et al
    Development and Validation of an RT-qPCR Assay for Rapid Detection and Quantification of Hepatitis C Virus RNA for Routine Testing in Moroccan Clinical Specimens.
    J Med Virol. 2018 Sep 29. doi: 10.1002/jmv.25326.
    PubMed     Abstract available


  157. WAHID B, Waqar M, Rasool N, Wasim M, et al
    Prevalence of TSH dysfunction among sofosbuvir-treated HCV infected patients: a real-world clinical experience.
    J Med Virol. 2018 Sep 19. doi: 10.1002/jmv.25319.
    PubMed     Abstract available


  158. PENG H, Zhang L, Feng Y, Tang H, et al
    A cross-sectional serum investigation of a clustering HCV infection in Southwest China.
    J Med Virol. 2018 Sep 11. doi: 10.1002/jmv.25315.
    PubMed     Abstract available


  159. KHOSRAVI A, Karimi-Sari H, Abedi-Andani M, Behnava B, et al
    Acute Changes in Cardiac Function by Direct-acting Antiviral Therapy for Hepatitis C Infected Thalassemia Patients.
    J Med Virol. 2018 Sep 11. doi: 10.1002/jmv.25314.
    PubMed     Abstract available


  160. GUOPING D, Xiaoshan L, Musa TH, Yu J, et al
    The Nationwide Distribution and Trends of Hepatitis C Virus Genotypes in Mainland China.
    J Med Virol. 2018 Sep 7. doi: 10.1002/jmv.25311.
    PubMed     Abstract available


  161. SASAKI R, Meyer K, Moriyama M, Kato N, et al
    Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
    J Med Virol. 2018 Sep 7. doi: 10.1002/jmv.25310.
    PubMed     Abstract available


  162. LI Y, Zeng Y, Zeng G, Li J, et al
    The Effects of Direct-Acting Antiviral Agents on the Frequency of Myeloid-Derived Suppressor Cells and Natural Killer Cells in Patients with Chronic Hepatitis C.
    J Med Virol. 2018 Sep 1. doi: 10.1002/jmv.25302.
    PubMed     Abstract available


    August 2018
  163. CANGIN C, Focht B, Harris R, Strunk JA, et al
    Hepatitis E Seroprevalence in the United States: Results for Immunoglobulins IgG and IgM.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25299.
    PubMed     Abstract available


  164. TANG X, Yan L, Li H, Du L, et al
    Increased Expression of Phosphoenolpyruvate Carboxykinase Cytoplasmic Isoform by Hepatitis B Virus X Protein Affects HBV Replication.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25300.
    PubMed     Abstract available


  165. GOURARI S, Brichler S, Le Gal F, Abdou-Chekaraou SM, et al
    Hepatitis B Virus and Hepatitis Delta Virus (HDV) Subtypes Circulating in Algeria and Seroprevalence of HDV Infection.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25301.
    PubMed     Abstract available


  166. CELLA E, Golgochvea-Markova E, Sagnelli C, Scolamacchia V, et al
    Human hepatitis E virus circulation in Bulgaria: deep Bayesian phylogenetic analysis for viral spread control in the country.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25296.
    PubMed     Abstract available


  167. ELBAZ T, Abdo M, Omar H, Hassan EA, et al
    Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
    J Med Virol. 2018 Aug 23. doi: 10.1002/jmv.25287.
    PubMed     Abstract available


  168. JORDIER F, Deligny ML, Barre R, Robert C, et al
    Human pegivirus (HPgV) isolates characterized by deep sequencing from HCV- and HIV-RNA positive blood donations, France.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25290.
    PubMed     Abstract available


  169. CASTRO VOL, Tejada-Strop A, Weis SMS, Stabile AC, et al
    Evidence of hepatitis E virus infections among persons who use crack cocaine from the Midwest region of Brazil.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25288.
    PubMed     Abstract available


  170. EL-HEFNY MA, Fouad SA, Hussein TD, Abdel-Hameed R, et al
    Circulating miRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25294.
    PubMed     Abstract available


  171. JIN J, Xu H, Wu R, Niu J, et al
    Aberrant DNA methylation profile of hepatitis B virus infection.
    J Med Virol. 2018 Aug 17. doi: 10.1002/jmv.25284.
    PubMed     Abstract available


  172. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25278.
    PubMed     Abstract available


  173. KAHYESH-ESFANDIARY R, Sadigh ZA, Esghaei M, Bastani MN, et al
    Detection of HCV Genome in Peripheral Blood Mononuclear Cells of Iranian Seropositive and HCV RNA negative in Plasma of Patients with Beta-thalassemia Major: Occult HCV Infection.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25279.
    PubMed     Abstract available


  174. LU T, Han Y, Zhang R, Zhang K, et al
    Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real-time PCR assay.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25280.
    PubMed     Abstract available


  175. FLORES GL, Cruz HM, Miguel JC, Potsch DV, et al
    Assessing Hepatitis B immunity using dried blood spot samples from HIV(+) individuals.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25275.
    PubMed     Abstract available


  176. PRAKASH S, Shukla S, Ramakrishna V, Jain A, et al
    Distribution of Hepatitis C Genotypes in Uttar Pradesh, India; Rare Genotype 4 Detected.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25277.
    PubMed     Abstract available


  177. YANG D, Hu T, Wu X, Li K, et al
    Droplet digital polymerase chain reaction for detection of clinical hepatitis B virus DNA samples.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25276.
    PubMed     Abstract available


    July 2018
  178. HARDTKE S, Rocco R, Ogata J, Braga S, et al
    Risk factors and seroprevalence of Hepatitis E evaluated in frozen serum samples (2002-2003) of pregnant women compared to female blood donors in a Southern Region of Brazil.
    J Med Virol. 2018 Jul 31. doi: 10.1002/jmv.25274.
    PubMed     Abstract available


  179. CHIHAB H, Jadid FZ, Foka P, Zaidane I, et al
    PD-1 3'untranslated region polymorphism is associated with spontaneous clearance of Hepatitis B virus infection.
    J Med Virol. 2018 Jul 17. doi: 10.1002/jmv.25265.
    PubMed     Abstract available


  180. MORIO K, Imamura M, Kawakami Y, Nakamura Y, et al
    Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
    J Med Virol. 2018 Jul 17. doi: 10.1002/jmv.25267.
    PubMed     Abstract available


  181. HASHEM M, Zaghla H, Zakaria Z, Allam WR, et al
    High spontaneous clearance of symptomatic iatrogenic acute hepatitis C genotype 4 infection.
    J Med Virol. 2018 Jul 16. doi: 10.1002/jmv.25270.
    PubMed     Abstract available


  182. YAMASAKI K, Tanaka J, Kurisu A, Akita T, et al
    Natural course of persistent hepatitis B virus infection in HBe antigen-positive and -negative cohorts in Japan based on the Markov model.
    J Med Virol. 2018 Jul 11. doi: 10.1002/jmv.25260.
    PubMed     Abstract available


  183. ZHAO N, Zheng W, Wu D, Wang X, et al
    Clinical value of HCcAg levels in monitoring acute hepatitis C spontaneous clearance or treatment-induced clearance.
    J Med Virol. 2018 Jul 11. doi: 10.1002/jmv.25256.
    PubMed     Abstract available


  184. JOGEDA EL, Avi R, Pauskar M, Kallas E, et al
    Association of IFNlambda4 rs12979860 Polymorphism with the Acquisition of HCV and HIV Infections among People Who Inject Drugs.
    J Med Virol. 2018 Jul 10. doi: 10.1002/jmv.25258.
    PubMed     Abstract available


  185. EL BATAE H, Amer I, Kobtan A, Saied SM, et al
    Seroprevalence of hepatitis C virus among the newcomer students, Kafrelsheikh University, Egypt.
    J Med Virol. 2018 Jul 7. doi: 10.1002/jmv.25249.
    PubMed     Abstract available


    June 2018
  186. DEGEFA B, Gebreeyesus T, Gebremedhin Z, Melkamu G, et al
    Prevalence of hepatitis B virus, hepatitis C virus and human immunodeficiency virus among blood donors of Mekelle blood bank, Northern Ethiopia: A three year retrospective study.
    J Med Virol. 2018 Jun 15. doi: 10.1002/jmv.25248.
    PubMed     Abstract available


  187. ZHANG W, Huang J, Wang M, Song D, et al
    Characterization of monocytic and granulocytic subsets of myeloid-derived suppressor cells in blood donors with occult hepatitis B virus infection.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25242.
    PubMed     Abstract available


  188. KIM HY, Yoo JJ, Oh S, Yu SJ, et al
    Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25241.
    PubMed     Abstract available


  189. WAKED I, Esmat G, Fouad R, Allam N, et al
    Change in hepatic profile in hepatitis C virus genotype 4 patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: a subanalysis of the AGATE-II study.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25243.
    PubMed     Abstract available


    May 2018
  190. CREMER J, Hofstraat SHI, van Heiningen F, Veldhuijzen IK, et al
    Genetic variation of Hepatitis B surface antigen among acute and chronic hepatitis B virus infections in the Netherlands.
    J Med Virol. 2018 May 24. doi: 10.1002/jmv.25232.
    PubMed     Abstract available


  191. LARSSON SB, Tripodi G, Raimondo G, Saitta C, et al
    Integration of hepatitis B virus DNA in chronically infected patients assessed by Alu-PCR.
    J Med Virol. 2018 May 24. doi: 10.1002/jmv.25227.
    PubMed     Abstract available


  192. MARYAM M, Idrees M
    Study of promoter hypomethylation profiles of RAS oncogenes in Hepatocellular Carcinoma derived from Hepatitis C virus genotype 3a in Pakistani population.
    J Med Virol. 2018 May 9. doi: 10.1002/jmv.25221.
    PubMed     Abstract available


  193. CELLA E, Riva E, Angeletti S, Fogolari M, et al
    Genotype I Hepatitis A virus introduction in Italy: Bayesian phylogenetic analysis to date different epidemics.
    J Med Virol. 2018 May 8. doi: 10.1002/jmv.25220.
    PubMed     Abstract available


  194. CAO D, Ni YY, Walker M, Huang YW, et al
    Roles of the genomic sequence surrounding the stem-loop structure in the junction region including the 3' terminus of ORF1 in hepatitis E virus replication.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25215.
    PubMed     Abstract available


  195. ALEM SA, Said M, Anwar I, Abdellatif Z, et al
    Improvement of LSM, ARFI measurements and non-invasive fibrosis markers after DAAs for HCV G4 recurrence post living donor liver transplantation: Egyptian cohort.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25210.
    PubMed     Abstract available


  196. DE DIEU LONGO J, Bouassa RM, Simaleko MM, Kouabosso A, et al
    Usefulness of simultaneous screening for HIV- and HCV- specific antibodies and HBsAg by capillary-based multiplex rapid diagnostic test to strengthen linkage-to-care in sub-Saharan patients attending sexually transmitted infections clinic.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25209.
    PubMed     Abstract available


  197. BURA M, Michalak M, Lagiedo-Zelazowska M, Bukowska A, et al
    HEV seroprevalence can significantly change after re-assessment.
    J Med Virol. 2018;90:783-785.
    PubMed    


  198. LAI A, Sagnelli C, Presti AL, Cella E, et al
    What is changed in HBV molecular epidemiology in Italy?
    J Med Virol. 2018;90:786-795.
    PubMed     Abstract available


    April 2018
  199. MOSITES E, Gounder P, Snowball M, Morris J, et al
    Hepatitis A vaccine immune response 22 years after vaccination.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25197.
    PubMed     Abstract available


  200. LAGO BV, Mello FCA, Barros TM, Mello VM, et al
    Hepatitis D infection in Brazil: prevalence and geographical distribution of anti-Delta antibody.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25196.
    PubMed     Abstract available


  201. NIGUSE S, Hailekiros H, Buruh G, Dejene T, et al
    Seroprevalence and risk factors of Hepatitis E Virus infection among pregnant women attending antenatal care in health facilities of Tigray, Northern Ethiopia.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25190.
    PubMed     Abstract available


  202. LIU K, Xie M, Lu X, Yu H, et al
    Mutations Within the Major Hydrophilic Region(MHR) of Hepatitis B Virus from individuals with simultaneous HBsAg and anti-HBs in Guangzhou, southern China.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25188.
    PubMed     Abstract available


  203. Z M, H K, E M, N B, et al
    Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About 8 cases resolved by a sequencing method.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25191.
    PubMed     Abstract available


  204. LAGO BV, Mello FCA, Barros TM, Mello VM, et al
    Hepatitis D infection in Brazil: prevalence and geographical distribution of anti-Delta antibody.
    J Med Virol. 2018 Apr 14. doi: 10.1002/jmv.25088.
    PubMed     Abstract available


  205. MOSITES E, Gounder P, Snowball M, Morris J, et al
    Hepatitis A vaccine immune response 22 years after vaccination.
    J Med Virol. 2018 Apr 12. doi: 10.1002/jmv.25089.
    PubMed     Abstract available


  206. VISCO-COMANDINI U, Lapa D, Lionetti R, Taibi C, et al
    Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols.
    J Med Virol. 2018 Apr 3. doi: 10.1002/jmv.25084.
    PubMed     Abstract available


  207. YANG R, Gao N, Chang Q, Meng X, et al
    The role of IDO, IL-10 and TGF-beta in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
    J Med Virol. 2018 Apr 3. doi: 10.1002/jmv.25083.
    PubMed     Abstract available


  208. GONG J, Liang YL, Zhou W, Jie Y, et al
    Prognostic value of neutrophil-to-lymphocyte ratio associated with prognosis in HBV-infected patients.
    J Med Virol. 2018;90:730-735.
    PubMed     Abstract available


  209. MATSUDA H, Hiramatsu K, Akazawa Y, Nosaka T, et al
    Genetic polymorphism and decreased expression of HLA class II DP genes are associated with HBV reactivation in patients treated with immunomodulatory agents.
    J Med Virol. 2018;90:712-720.
    PubMed     Abstract available


  210. CHEN W, Wang L, Niu Y, Ji G, et al
    Distribution of peripheral dendritic cells in patients with HBV infection or spleen and kidney deficiency.
    J Med Virol. 2018;90:706-711.
    PubMed     Abstract available


  211. LI Y, Liu S, Deng Q, Ling L, et al
    A sensitive colorimetric DNA biosensor for specific detection of the HBV gene based on silver-coated glass slide and G-quadruplex-hemin DNAzyme.
    J Med Virol. 2018;90:699-705.
    PubMed     Abstract available


    March 2018
  212. YANG N, Feng J, Zhou T, Li Z, et al
    Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients.
    J Med Virol. 2018 Mar 30. doi: 10.1002/jmv.25080.
    PubMed     Abstract available


  213. MARASCIO N, Pavia G, Romeo I, Talarico C, et al
    Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling.
    J Med Virol. 2018 Mar 25. doi: 10.1002/jmv.25073.
    PubMed     Abstract available


  214. DENG H, Deng X, Liu Y, Xu Y, et al
    Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China.
    J Med Virol. 2018 Mar 24. doi: 10.1002/jmv.25078.
    PubMed     Abstract available


  215. ANTONIO UL, Alicia OM, Antonio MJ, Elena GM, et al
    Presence of rare hepatitis C virus subtypes, 2j, 2k and 2r, in Mexico City as identified by sequencing.
    J Med Virol. 2018 Mar 6. doi: 10.1002/jmv.25070.
    PubMed     Abstract available


    February 2018
  216. COLOMBATTO P, Barbera C, Bortolotti F, Maina AM, et al
    HBV Pre-Core mutant in genotype-D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood.
    J Med Virol. 2018 Feb 28. doi: 10.1002/jmv.25068.
    PubMed     Abstract available


  217. LEE GH, Inoue M, Chong RH, Toh J, et al
    Pyrosequencing Method for Sensitive Detection of HBV Drug Resistance Mutations.
    J Med Virol. 2018 Feb 28. doi: 10.1002/jmv.25066.
    PubMed     Abstract available


  218. CORDIE A, Salama A, El-Sharkawy M, El-Nahaas SM, et al
    Comparing the efficiency of Fib-4, Egy-score, APRI and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C.
    J Med Virol. 2018 Feb 24. doi: 10.1002/jmv.25064.
    PubMed     Abstract available


  219. SHOUSHA HI, Abdelaziz RA, Azab SM, Khairy M, et al
    Effect of Treatment with Direct Acting Antivirals on Body Mass Index and Hepatic Steatosis in Chronic Hepatitis C.
    J Med Virol. 2018 Feb 22. doi: 10.1002/jmv.25062.
    PubMed     Abstract available


  220. ZHOU S, Ren L, Xia X, Miao Z, et al
    Hepatitis E virus infection in HIV-infected patients: a large cohort study in Yunnan province, China.
    J Med Virol. 2018 Feb 19. doi: 10.1002/jmv.25060.
    PubMed     Abstract available


  221. RAN M, Huang J, Liang H, Jiang J, et al
    Alcohol attenuates anti-HCV function of IFN-lambda1 through up-regulation of PLASy expression in human hepatic cells.
    J Med Virol. 2018 Feb 15. doi: 10.1002/jmv.25053.
    PubMed     Abstract available


  222. DE CASTRO SANT' ANNA C, de Almeida MKC, Ferreira P, de Oliveira RG, et al
    PREVALENCE OF OCCULT HEPATITIS B IN A POPULATION FROM THE BRAZILIAN AMAZON REGION.
    J Med Virol. 2018 Feb 15. doi: 10.1002/jmv.25051.
    PubMed     Abstract available


  223. GRECO L, Renteria SCU, Guarneri D, Orlandi A, et al
    HEV and HAV seroprevalence in men that have sex with men (MSM): an update from Milan, Italy.
    J Med Virol. 2018 Feb 15. doi: 10.1002/jmv.25052.
    PubMed     Abstract available


  224. MANCINELLI S, Pirillo MF, Liotta G, Andreotti M, et al
    ANTIBODY RESPONSE TO HEPATITIS B VACCINE IN HIV-EXPOSED INFANTS IN MALAWI AND CORRELATION WITH HBV INFECTION ACQUISITION.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25049.
    PubMed     Abstract available


  225. OGATA F, Akuta N, Kobayashi M, Fujiyama S, et al
    Amino Acid Substitutions in the Hepatitis C Virus Core Region Predict Hepatocarcinogenesis Following Eradication of HCV RNA by All-Oral Direct-Acting Antiviral Regimens.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25047.
    PubMed     Abstract available


  226. GRANDAL M, Pernas B, Tabernilla A, Marino A, et al
    Prevalence of NS5A Resistance Associated Substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on Current Therapeutic Strategies.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25048.
    PubMed     Abstract available


  227. ANASTASIOU OE, Widera M, Korth J, Kefalakes H, et al
    Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA.
    J Med Virol. 2018;90:282-290.
    PubMed     Abstract available


    January 2018
  228. BOGLIONE L, Cariti G, Ghisetti V, Burdino E, et al
    Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: a retrospective analysis.
    J Med Virol. 2018 Jan 31. doi: 10.1002/jmv.25038.
    PubMed     Abstract available


  229. SUN LJ, Yu JW, Shi YG, Zhang XY, et al
    Hepatitis C virus core protein induces dysfunction of liver sinusoidal endothelial cell by down-regulation of silent information regulator 1.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25034.
    PubMed     Abstract available


  230. MOUREZ T, Decroos A, Goria O, Montialoux H, et al
    Misidentification of recombinant hepatitis C virus leading to treatment failure with direct acting antivirals.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25035.
    PubMed     Abstract available


  231. MARCIANO S, Haddad L, Reggiardo MV, Peralta M, et al
    Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: a real world study.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25033.
    PubMed     Abstract available


  232. ALIDJINOU EK, Michel C, Canva V, Ajana F, et al
    Very slow decline of hepatitis B virus surface antigen and core related antigen in chronic hepatitis B patients successfully treated with nucleos(t)ide analogues.
    J Med Virol. 2018 Jan 9. doi: 10.1002/jmv.25028.
    PubMed     Abstract available


  233. MARIO S, Carmine M, Stefania P, Margherita M, et al
    VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS.
    J Med Virol. 2018 Jan 9. doi: 10.1002/jmv.25022.
    PubMed     Abstract available


  234. GAMIL M, Alboraie M, El-Sayed M, Elsharkawy A, et al
    Novel scores combining AFP with non-invasive markers for prediction of liver fibrosis in chronic hepatitis C patients.
    J Med Virol. 2018 Jan 6. doi: 10.1002/jmv.25026.
    PubMed     Abstract available


  235. OHYA K, Akuta N, Suzuki F, Fujiyama S, et al
    Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
    J Med Virol. 2018 Jan 5. doi: 10.1002/jmv.25023.
    PubMed     Abstract available


    December 2017
  236. ZHU MY, Chen PZ, Li J, Yu DM, et al
    Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-alpha treatment in HBeAg-positive chronic hepatitis B patients.
    J Med Virol. 2017 Dec 16. doi: 10.1002/jmv.25010.
    PubMed     Abstract available


  237. MATHUR P, Emmanuel B, Sneller M, Zhang X, et al
    Recovery of Hepatitis C Specific T-cell Responses after Rituximab Therapy in Hepatitis C Mixed Cryoglobulinemic Vasculitis.
    J Med Virol. 2017 Dec 13. doi: 10.1002/jmv.25002.
    PubMed     Abstract available


    November 2017
  238. ISHIGAMI M, Hayashi K, Honda T, Kuzuya T, et al
    Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
    J Med Virol. 2017 Nov 7. doi: 10.1002/jmv.24978.
    PubMed     Abstract available


  239. SU S, Fairley CK, Sasadeusz J, He J, et al
    HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    J Med Virol. 2017 Nov 1. doi: 10.1002/jmv.24988.
    PubMed     Abstract available


    October 2017
  240. KIM DY, Lee HW, Song JE, Kim BK, et al
    Switching from Tenofovir and Nucleoside Analogue Therapy to Tenofovir Monotherapy in Virologically Suppressed Chronic Hepatitis B Patients with Antiviral Resistance.
    J Med Virol. 2017 Oct 27. doi: 10.1002/jmv.24986.
    PubMed     Abstract available


  241. MEZGEBO TA, Niguse S, Kahsay AG, Hailekiros H, et al
    HEPATITIS B VIRUS INFECTION AND ASSOCIATED RISK FACTORS AMONG PREGNANT WOMEN ATTENDING ANTENATAL CARE IN HEALTH FACILITIES OF TIGRAY, NORTHERN ETHIOPIA.
    J Med Virol. 2017 Oct 27. doi: 10.1002/jmv.24987.
    PubMed     Abstract available


  242. GEWAID H, Mesalam AA, Ibrahim AA, Abdel Shafy DN, et al
    Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24977.
    PubMed     Abstract available


  243. SILVA RAD, de Souza Todao J, Kamitani FL, Benedito Silva AE, et al
    MOLECULAR CHARACTERIZATION OF HEPATITIS C VIRUS IN END-STAGE RENAL DISEASE PATIENTS UNDER HEMODIALYSIS.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24976.
    PubMed     Abstract available


  244. JAVAN B, Reza Kalani M, Shahbazi M
    Interleukin-1 Gene Cluster Haplotype Analysis in the Chronic Outcome Prediction of the Hepatitis B Virus Infection.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24972.
    PubMed     Abstract available


  245. AL-RADDADI RM, Dashash NA, Alghamdi HA, Al-Raddadi ZM, et al
    Hepatitis C virus infection in Jeddah City, Saudi Arabia: Seroprevalence and knowledge.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24973.
    PubMed     Abstract available


  246. CARRASCO I, Arias A, Benitez-Gutierrez L, Lledo G, et al
    Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.
    J Med Virol. 2017 Oct 9. doi: 10.1002/jmv.24971.
    PubMed     Abstract available


  247. AMPONSAH-DACOSTA E, Selabe SG, Mphahlele MJ
    Evolution of the serologic and virologic course of occult HBV infection in therapy experienced HIV co-infected patients.
    J Med Virol. 2017 Oct 2. doi: 10.1002/jmv.24956.
    PubMed     Abstract available


    September 2017
  248. RAHMAN M, Hossain ME, Afrad MH, Hasan R, et al
    Hepatitis C Virus infections among clients attending an HIV testing and counseling center in Dhaka, Bangladesh.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24955.
    PubMed     Abstract available


  249. CIANCIO A, Bosio R, Bo S, Pellegrini M, et al
    SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24954.
    PubMed     Abstract available


  250. ALVARADO-ESQUIVEL C, Sanchez-Anguiano LF, Hernandez-Tinoco J, Alvarado-Felix AO, et al
    Seroepidemiology of hepatitis E virus infection in pigs in Durango State, Mexico.
    J Med Virol. 2017 Sep 15. doi: 10.1002/jmv.24951.
    PubMed     Abstract available


  251. OGASAWARA N, Kobayashi M, Akuta N, Kominami Y, et al
    Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    J Med Virol. 2017 Sep 14. doi: 10.1002/jmv.24950.
    PubMed     Abstract available


  252. AHMED AM, Doheim MF, Mattar OM, Sherif NA, et al
    Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    J Med Virol. 2017 Sep 11. doi: 10.1002/jmv.24947.
    PubMed     Abstract available


  253. SCHULZ TR, Edwards R, Thurnheer MC, Yuen L, et al
    Hepatitis B amongst Immigrants from Myanmar: Genotypes and their Clinical Relevance.
    J Med Virol. 2017 Sep 8. doi: 10.1002/jmv.24939.
    PubMed     Abstract available


  254. CAVARETTO LDSP, Motta-Castro ARC, Teles SA, de Souza FQ, et al
    Epidemiological and molecular analysis of hepatitis B virus infection in manicurists in Central Brazil.
    J Med Virol. 2017 Sep 8. doi: 10.1002/jmv.24940.
    PubMed     Abstract available


  255. ZHANG K, Liu Y, Chen R, Li Q, et al
    Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV) S-gene mutants isolated from individuals with occult HBV infection.
    J Med Virol. 2017 Sep 6. doi: 10.1002/jmv.24936.
    PubMed     Abstract available


    August 2017
  256. MA X, Sun D, Li C, Ying J, et al
    Chronic hepatitis B virus infection and preterm labor(birth) in pregnant women-An updated systematic review and meta-analysis.
    J Med Virol. 2017 Aug 29. doi: 10.1002/jmv.24927.
    PubMed     Abstract available


  257. DEHGHANI-DEHEJ F, Sarvari J, Esghaei M, Hosseini SY, et al
    Presence of Different Hepatitis C Virus Genotypes in Plasma and Peripheral Blood Mononuclear Cell Samples of Iranian Patients with HIV Infection.
    J Med Virol. 2017 Aug 28. doi: 10.1002/jmv.24925.
    PubMed     Abstract available


  258. SHEPHERD SJ, McDonald SA, Palmateer NE, Gunson RN, et al
    HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24919.
    PubMed     Abstract available


  259. SCHNELL G, Tripathi R, Krishnan P, Beyer J, et al
    Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24923.
    PubMed     Abstract available


  260. MAHMUD S, Kanaani ZA, Chemaitelly H, Chaabna K, et al
    Hepatitis C Virus Genotypes in the Middle East and North Africa: Distribution, Diversity, and Patterns.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24921.
    PubMed     Abstract available


  261. ZHAO C, Geng Y, Huang W, Ma H, et al
    Valuable Antibody Detection Method for Classifying Hepatitis E Virus Genotypes.
    J Med Virol. 2017 Aug 17. doi: 10.1002/jmv.24915.
    PubMed     Abstract available


  262. YANG T, Chen Q, Li D, Wang T, et al
    High prevalence of syphilis, HBV and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital.
    J Med Virol. 2017 Aug 9. doi: 10.1002/jmv.24912.
    PubMed     Abstract available


  263. JOSE-ABREGO A, Panduro A, Fierro NA, Roman S, et al
    High prevalence of HBV infection, detection of subgenotypes F1b, A2 and D4 and differential risk factors among Mexican risk populations with low socioeconomic status.
    J Med Virol. 2017 Aug 9. doi: 10.1002/jmv.24913.
    PubMed     Abstract available


  264. TSATSRALT-OD B, Primadharsini PP, Nishizawa T, Ohnishi H, et al
    Distinct changing profiles of hepatitis A and E virus infection among patients with acute hepatitis in Mongolia: The first report of the full genome sequence of a novel genotype 1 hepatitis E virus strain.
    J Med Virol. 2017 Aug 4. doi: 10.1002/jmv.24907.
    PubMed     Abstract available


    July 2017
  265. WEHMEYER MH, Ingiliz P, Christensen S, Hueppe D, et al
    Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03).
    J Med Virol. 2017 Jul 15. doi: 10.1002/jmv.24903.
    PubMed     Abstract available


  266. LISBOA NETO G, M Malta F, Gomes-Gouvea MS, F Noble C, et al
    CHARACTERIZATION OF CLINICAL PREDICTORS OF NATURALLY OCCURRING NS3/NS4A PROTEASE POLYMORPHISM IN GENOTYPE 1 HEPATITIS C VIRUS MONO AND HIV CO-INFECTED PATIENTS.
    J Med Virol. 2017 Jul 12. doi: 10.1002/jmv.24900.
    PubMed     Abstract available


  267. LU J, Xiang X, Cao Z, Wang W, et al
    Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China.
    J Med Virol. 2017 Jul 3. doi: 10.1002/jmv.24894.
    PubMed     Abstract available


  268. OSAWA M, Akuta N, Suzuki F, Fujiyama S, et al
    Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.
    J Med Virol. 2017 Jul 1. doi: 10.1002/jmv.24890.
    PubMed     Abstract available


    June 2017
  269. CHEN T, Xun Z, Lin J, Fu Y, et al
    Association between mitochondrial DNA content and baseline serum levels of HBsAg in chronic hepatitis B infection.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24886.
    PubMed     Abstract available


  270. KAN H, Imamura M, Kawakami Y, Daijo K, et al
    Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24885.
    PubMed     Abstract available


  271. COSTANTINO A, Coppola N, Spada E, Bruni R, et al
    Hepatitis A virus strains circulating during 1997-2015 in Campania, a Southern Italy region with periodic outbreaks.
    J Med Virol. 2017 Jun 16. doi: 10.1002/jmv.24880.
    PubMed     Abstract available


  272. ADEYEMI OO, Herod MR, Oladiji F, Fakunle YM, et al
    A multi-template multiplex PCR assay for hepatitis B virus and human beta-globin.
    J Med Virol. 2017 Jun 15. doi: 10.1002/jmv.24877.
    PubMed     Abstract available


  273. AHN HS, Park BJ, Han SH, Kim YH, et al
    Prevalence and Genetic Features of Rabbit Hepatitis E Virus in Korea.
    J Med Virol. 2017 Jun 15. doi: 10.1002/jmv.24875.
    PubMed     Abstract available


  274. CAI Y, Qin SY, Qian A, Xu P, et al
    Seroprevalence and risk factors of hepatitis E virus infection among the Korean, Manchu, Mongol and Han ethnic groups in eastern and northeastern China.
    J Med Virol. 2017 Jun 3. doi: 10.1002/jmv.24871.
    PubMed     Abstract available


  275. SAGNELLI C, Ciccozzi M, Coppola N, Minichini C, et al
    Molecular diversity in irregular or refugee immigrant patients with HBV-genotype-E infection living in the metropolitan area of Naples.
    J Med Virol. 2017;89:1015-1024.
    PubMed     Abstract available


  276. MOBARAK L, Omran D, Nabeel MM, Zakaria Z, et al
    Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease.
    J Med Virol. 2017;89:1062-1068.
    PubMed     Abstract available


    May 2017
  277. SHI X, Jiao B, Chen Y, Li S, et al
    MxA Is A Positive Regulator of Type I IFN Signaling in HCV Infection.
    J Med Virol. 2017 May 31. doi: 10.1002/jmv.24867.
    PubMed     Abstract available


  278. HUANG X, Ma C, Zhang Q, Shi Q, et al
    Impact of "a" Determinant Mutations on Detection of Hepatitis B Surface Antigen (HBsAg) in HBV Strains from Chinese Patients with Occult Hepatitis B.
    J Med Virol. 2017 May 17. doi: 10.1002/jmv.24859.
    PubMed     Abstract available


  279. DOS SANTOS MIMA, Rugiere SP, Stocker A, Schinoni MI, et al
    Mutations Associated With Drug Resistance and Prevalence of Vaccine Escape Mutations In Patients With Chronic Hepatitis B Infection.
    J Med Virol. 2017 May 13. doi: 10.1002/jmv.24853.
    PubMed     Abstract available


  280. KAR P, Kumar D, Gumma PK, Chowdhury SJ, et al
    Down regulation of TRIF, TLR3 and MAVS in HCV infected liver correlates with the outcome of infection.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24849.
    PubMed     Abstract available


  281. HUDSON B, Walker AJ, Irving WL
    Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24848.
    PubMed     Abstract available


  282. RAZIKY ME, Zayed NA, Baki AA, Mansour SA, et al
    ITPA Gene polymorphism (94C>A) Effects on Ribavirin-Induced Anemia during Therapy in Egyptian Patients with Chronic Hepatitis C.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24844.
    PubMed     Abstract available


  283. SCOGNAMIGLIO P, Piselli P, Fusco M, Pisanti FA, et al
    DECLINING UNAWARENESS OF HCV-INFECTION PARALLEL TO DECLINING PREVALENCE IN SOUTHERN ITALY.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24840.
    PubMed     Abstract available


  284. TRIPODI G, Larsson SB, Norkrans G, Lindh M, et al
    Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24841.
    PubMed     Abstract available


  285. LONG F, Yu W, Yang C, Wang J, et al
    High prevalence of Hepatitis E virus infection in goats.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24843.
    PubMed     Abstract available


    April 2017
  286. SHINDANO TA, Horsmans Y, Kabamba BM
    GENETIC AND PHYLOGENIC CHARACTERISATION OF HEPATITIS B VIRUS IN THE EASTERN PART OF THE DEMOCRATIC REPUBLIC OF CONGO.
    J Med Virol. 2017 Apr 29. doi: 10.1002/jmv.24837.
    PubMed     Abstract available


  287. CHAN MC, Cheng FW, Sze KH, Wong AH, et al
    Hepatitis B infection acquired after haematopioetic stem cell transplant through horizontal mode.
    J Med Virol. 2017 Apr 29. doi: 10.1002/jmv.24835.
    PubMed     Abstract available


  288. DE PASCHALE M, Manco MT, Arpino O, Ricucci V, et al
    Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24831.
    PubMed     Abstract available


  289. WANG J, Zhang H, Zhang Y, Jiang D, et al
    Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24830.
    PubMed     Abstract available


  290. JIAO X, Fan Z, Chen H, He P, et al
    Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24829.
    PubMed     Abstract available


  291. EL-MOWAFY M, Elgaml A, El-Mesery M, Elegezy M, et al
    Molecular analysis of Hepatitis B virus sub-genotypes and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura.
    J Med Virol. 2017 Apr 8. doi: 10.1002/jmv.24828.
    PubMed     Abstract available


    March 2017
  292. MENDIZABAL M, Haddad L, Gallardo PE, Ferrada A, et al
    Ombitasvir/paritaprevir/ritonavir/dasabuvir +/- ribavirin is safe and effective in HCV infected patients in a real-life cohort from Latin America.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24816.
    PubMed     Abstract available


  293. KHALIFA RH, Labib DA, Kamel MA, Shahin RM, et al
    Role of ApoB-516C/T promoter gene polymorphism in the risk of Hepatitis C virus infection in Egyptian patients and in gender susceptibility.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24815.
    PubMed     Abstract available


  294. HIRAMATSU K, Matsuda H, Nemoto T, Nosaka T, et al
    Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C.
    J Med Virol. 2017 Mar 22. doi: 10.1002/jmv.24814.
    PubMed     Abstract available


  295. EIJSVOOGEL NB, Hollegien MI, Bok LA, Derksen-Lubsen A, et al
    Declining antibody levels after hepatitis B vaccination in Down syndrome: a need for booster vaccination?
    J Med Virol. 2017 Mar 21. doi: 10.1002/jmv.24813.
    PubMed     Abstract available


  296. CICCOZZI M, Chaouch H, Lo Presti A, Taffon S, et al
    Evolutionary dynamics of HBV-D7 subgenotype in Tunisia.
    J Med Virol. 2017;89:469-475.
    PubMed     Abstract available


  297. ZHANG Y, Wang L, Zeng H, Gong W, et al
    Development and validation of a new serum standard for the measurement of anti-HEV antibodies in animals.
    J Med Virol. 2017;89:497-501.
    PubMed     Abstract available


    September 2016
  298. ROUABHIA S, Chaabna K
    Hepatitis C infection in eastern Algeria: Between statistics and reality.
    J Med Virol. 2016 Sep 14. doi: 10.1002/jmv.24686.
    PubMed     Abstract available


  299. JOGEDA EL, Huik K, Pauskar M, Kallas E, et al
    The prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe.
    J Med Virol. 2016 Sep 7. doi: 10.1002/jmv.24683.
    PubMed     Abstract available


    June 2016
  300. KIM MN, Park JY, Ahn SH, Kim BK, et al
    Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy.
    J Med Virol. 2016 Jun 30. doi: 10.1002/jmv.24616.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: